Schulman Associates IRB, Inc. Acquires Independent IRB, Inc.
Schulman Associates Institutional Review Board, Inc. announced the acquisition of Florida-based Independent Investigational Review Board, Inc. The transaction allows both organizations, which protect the rights of human research subjects, to provide a more comprehensive suite of review services for pharmaceutical, medical device, Contract Research Organization (CRO) and clinical research site customers.
"The strengths of the two organizations are remarkably complimentary," said Michael Woods, President and CEO of Schulman. "We are very excited by the added resources and capabilities Independent brings to the combined company."
With offices in Cincinnati, Ohio, and Plantation, Fl., the combined organization will aim to provide the highest level of quality research review services for a very broad range of therapeutic areas and types of human subject research. Separately, each organization is accredited by Association for the Accreditation of Human Research Protection Programs (AAHRPP), and each has a clean recent audit history with Food and Drug Administration. Both organizations, in business more than 20 years, also enjoy strong reputations for performing thoughtful and rigorous reviews while providing the highest level of customer service available.
"Joining with Schulman allows Independent to provide the advantages of enhanced WebPortal and IT features to our established customer base," said Kim Lerner, outgoing CEO of Independent.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
